Naïve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team)
Child-Pugh score of 5 or 6 (ie, Child-Pugh A)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
You may not be if
Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
Prior allogenic stem cell or solid organ transplantation
Untreated symptomatic central nervous system (CNS) metastases
Clinically significant ascites as defined by:
i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment
